Bispecific antibody
A bispecific antibody targeting IL-18 and TL1A effectively addresses the challenge of managing synergistic cytokine-mediated inflammation by simultaneously neutralizing both, offering improved therapeutic efficacy in chronic inflammatory diseases.
Patent Information
- Application Number
- PCT/GB2026/050783
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
There is a significant unmet need for novel biologies capable of modulating multifactorial immune responses in chronic inflammatory diseases, particularly those mediated by IL-18 and TL1A, as existing therapies targeting these cytokines individually are inadequate in managing their synergistic effects.
Development of a bispecific antibody that simultaneously binds and neutralizes both IL-18 and TL1A, leveraging technologies like controlled Fab-arm exchange, Duobody, CrossMab, and WuxiBody to generate antibodies with specific antigen-binding domains for IL-18 and TL1A, potentially reducing excessive inflammation and restoring immune balance.
The bispecific antibody offers superior clinical outcomes in treating inflammatory diseases such as IBD, asthma, and fibrotic diseases by concurrently inhibiting both cytokines, minimizing off-target effects and providing broader applications in autoimmune conditions and cancers.
Smart Images

Figure GB2026050783_12112026_PF_FP_ABST
Abstract
Description
[0001] Bispecific Antibody
[0002] The invention relates to bispecific antibodies, and particularly to antibodies that specifically bind to IL-18 and TL1A. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis. More specifically, the invention pertains to a bispecific antibody that targets IL-18 and TL1A, and can be used for the treatment of diseases associated with excessive or dysregulated IL-18 and TL1A activity, including inflammatory bowel disease (IBD), asthma, and fibrotic diseases.
[0003] Cytokines play a critical role in regulating immune responses and maintaining homeostasis. Dysregulation of cytokine signalling is implicated in a wide range of inflammatory and autoimmune diseases, as well as in cancer and infectious diseases. Interleukin-18 (IL-18) and Tumour Necrosis Factor-like cytokine 1A (TL1A) are two such cytokines that have independently been shown to contribute to pro-inflammatory pathways and immune modulation.
[0004] IL-18 is a member of the IL-1 family of cytokines and is primarily produced by macrophages and other myeloid cells. It acts by binding to its receptor complex, composed of IL-18RO and IL-18R0, to activate downstream signalling pathways such as NF-KB and MARK. IL-18 plays a pivotal role in the induction of IFN-y, promoting Thl-type immune responses. Elevated IL-18 levels have been associated with chronic inflammatory conditions such as rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus, and psoriasis (Landy et al., 2024; Wang et al., 2023).
[0005] TL1A (TNFSF15) is a member of the TNF superfamily and signals through its receptor, Death Receptor 3 (DR3), which is expressed on various T cell subsets including effector and regulatory T cells. TL1A is known to co-stimulate T cell activation, proliferation, and cytokine production, especially in the context of mucosal immunity. TL1A / DR3 interactions are also implicated in a range of pathological conditions including inflammatory bowel disease (IBD), asthma, and fibrotic diseases (Clarke et al., 2018; Ruiz Perez et al., 2024).
[0006] Recent evidence suggests that IL-18 and TL1A may have synergistic effects in promoting T cell-driven inflammation, particularly in mucosal tissues such as the gut. Their combined activity may exacerbate the immune dysregulation observed in diseases like Crohn's disease and ulcerative colitis. Moreover, their roles in differentyet converging signalling pathways present a compelling opportunity for dual-targeted intervention (Papadakis et al., 2005).
[0007] Bispecific antibodies, which can simultaneously bind two different antigens or epitopes, have emerged as a powerful therapeutic modality. They offer advantages in selectively modulating complex disease pathways by targeting multiple mediators simultaneously. A bispecific antibody targeting both IL-18 and TL1A could provide a novel therapeutic approach by concurrently inhibiting two key pro-inflammatory cytokines involved in overlapping immune pathways. There remains a significant unmet need for novel biologies capable of modulating multifactorial immune responses in chronic inflammatory diseases. The development of a bispecific antibody targeting IL-18 and TL1A offers a promising solution for treating such diseases more effectively than monotherapies.
[0008] There is, therefore, the need for improved compositions for targeting IL-18 and TL1A and treating diseases mediated by these two cytokines.
[0009] This invention pertains to a novel IL-18 / TL1A bispecific antibody designed to bind and neutralize both IL-18 and TL1A. By targeting both cytokines, the antibody has the potential to reduce excessive inflammation, alleviate symptoms of chronic diseases such as inflammatory bowel disease (IBD), asthma, and fibrotic diseases, and restore immune balance. The dual targeting approach may offer superior clinical outcomes compared to monoclonal antibodies targeting either cytokine alone, while minimizing the risk of adverse effects associated with off-target activity. In addition to its therapeutic potential in inflammatory bowel disease (IBD), asthma, and fibrotic diseases, this bispecific antibody may have broader applications in other inflammatory diseases, autoimmune conditions, and cancers, where dysregulation of IL-18 and TL1A contributes to disease pathology.
[0010] Accordingly, in a first aspect of the invention, there is provided a bispecific antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that specifically binds to Interleukin-18 (IL-18) or a functional fragment or variant thereof, and a second antigen-binding domain that specifically binds to Tumour Necrosis Factor-like cytokine 1A (TL1A) or a functional fragment or variant thereof.
[0011] As shown in the Examples, the inventors have developed bispecific antibodies that are capable of binding to IL-18 and TL1A, or a functional fragment or variant thereof, and inhibiting IL-18 and TL1A function. The six CDR, VH, VL, CH and CL sequences of thefirst (IL-18) and second (TL1A) antigen-binding domains are summarised in the table shown in Figure 12. The inventors have used several different technologies to generate these bispecific antibodies, including controlled Fab-arm exchange (cFAE), Duobody, CrossMab, and WuxiBody. Accordingly, with reference to Figure 12, the bispecific antibodies according to the invention are generated as follows: (i) "Al" IL-18 antigen binding domain (duobody) paired with "B1" TL1A antigen binding domain (duobody); (ii) "A2" IL-18 antigen binding domain (CrossMab regular arm) paired with "B2" TL1A antigen binding domain (CrossMab cross arm); (iii) "A3" IL-18 antigen binding domain (CrossMab cross arm) paired with "B3" TL1A antigen binding domain (CrossMab regular arm); (iv) "A4" IL-18 antigen binding domain (WuxiBody regular arm) paired with "B4"TL1A antigen binding domain (WuxiBody Wuxi arm); and (v) "A5" IL-18 antigen binding domain (WuxiBody Wuxi arm) paired with "B5"TL1A antigen binding domain (WuxiBody regular arm).
[0012] The invention extends to both whole antibodies (i.e. immunoglobulins) with immunospecificity for IL-18 and TL1A, or functional fragments or variants thereof, as well as to antigen-binding fragments or regions of the corresponding full-length antibody.
[0013] The antibody or antigen-binding fragment thereof may be monovalent, divalent or polyvalent. Monovalent antibodies are dimers (HL) comprising a heavy (H) chain associated by a disulphide bridge with a light chain (L). Divalent antibodies are tetramer (H2L2) comprising two dimers associated by at least one disulphide bridge. Polyvalent antibodies may also be produced, for example by linking multiple dimers. The basic structure of an antibody molecule consists of two identical light chains and two identical heavy chains which associate non-covalently and can be linked by disulphide bonds. Each heavy and light chain contains an amino-terminal variable region of about 110 amino acids, and constant sequences in the remainder of the chain. The variable region includes several hypervariable regions, or Complementarity Determining Regions (CDRs), that form the antigen-binding site of the antibody molecule and determine its specificity for the antigen, i.e. IL-18 and TL1A (e.g. an epitope). On either side of the CDRs of the heavy and light chains is a framework region, a relatively conserved sequence of amino acids that anchors and orients the CDRs. Antibody fragments may include a bi-specific antibody (BsAb) or a chimeric antigen receptor (CAR).
[0014] The heavy chain constant region typically comprises three domains, CHI, CH2, and CHS. Each light chain typically comprises a light chain variable region (VL) and a light chainconstant region. The light chain constant region typically comprises one domain, abbreviated CL.
[0015] Each heavy chain and light chain generally comprise three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1 - CDR1 - FR2 -CDR2 - FR3 - CDR3 - FR4. The CDRs are involved in antigen binding and confer antigen specificity and binding affinity to the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, incorporated by reference in its entirety.
[0016] The heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated a, 6, e, y, and p, respectively. The IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2. In one embodiment, the antibody is of the IgG antibody class. In one embodiment, the antibody is of the IgGl antibody class.
[0017] The light chain from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.
[0018] The constant region consists of one of five heavy chain sequences (p, y,
[0019]
[0020] a, or e) and one of two light chain sequences (K or A). The heavy chain constant region sequences determine the isotype of the antibody and the effector functions of the molecule.
[0021] In some embodiments, the antibody or antigen-binding fragment thereof is isolated or purified.
[0022] In one embodiment, the antibody or antigen-binding fragment thereof comprises a polyclonal antibody, or an antigen-binding fragment thereof. The antibody or antigenbinding fragment thereof may be generated in a rabbit, mouse or rat.
[0023] In another embodiment, the antibody or antigen-binding fragment thereof comprises a monoclonal antibody or antigen-binding fragment thereof. In some embodiments, the antibody of the invention is a human antibody. As used herein, the term "human antibody" can mean an antibody, such as a monoclonal antibody, which comprises substantially the same heavy and light chain CDR amino acid sequences as found in a particular human antibody exhibiting immunospecificity for IL-18 or TL1A, or a variantor fragment thereof. An amino acid sequence, which is substantially the same as a heavy or light chain CDR, exhibits a considerable amount of sequence identity when compared to a reference sequence. Such identity is definitively known or recognizable as representing the amino acid sequence of the particular human antibody.
[0024] Substantially the same heavy and light chain CDR amino acid sequence can have, for example, minor modifications or conservative substitutions of amino acids. Such a human antibody maintains its function of selectively binding to IL-18 or TL1A, or a variant or fragment thereof.
[0025] The term "human monoclonal antibody" can include a monoclonal antibody with substantially or entirely human CDR amino acid sequences produced, for example by recombinant methods such as production by a phage library, by lymphocytes or by hybridoma cells.
[0026] The term "monoclonal antibody" refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (by so-called "affinity maturation"), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.
[0027] The term "humanised antibody" can mean an antibody from a non-human species (e.g. mouse or rabbit) whose protein sequences have been modified to increase their similarity to antibodies produced naturally in humans.
[0028] The antibody may be a recombinant antibody. The term "recombinant human antibody" can include a human antibody produced using recombinant DNA technology.
[0029] The term "antigen-binding region" can mean a region of the antibody having specific binding affinity for its target antigen, for example, IL-18 and TL1A, or variants or fragments thereof. In some embodiments, the fragment is an epitope. The antigen-binding region may be a hypervariable CDR or a functional portion thereof. The term "functional portion" of a CDR can mean a sequence within the CDR which shows specific affinity for the target antigen. The functional portion of a CDR may comprise a ligand which specifically binds to IL-18 and TL1A, or variants or fragments thereof.
[0030] The term "CDR" can mean a hypervariable region in the heavy and light variable chains. There may be one, two, three or more CDRs in each of the heavy and light chains of the antibody. Normally, there are at least three CDRs on each chain which, when configured together, form the antigen-binding site, i.e. the three-dimensional combining site with which the antigen binds or specifically reacts. It has however been postulated that there may be four CDRs in the heavy chains of some antibodies.
[0031] The definition of CDR also includes overlapping or subsets of amino acid residues when compared against each other. The exact residue numbers which encompass a particular CDR or a functional portion thereof will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.
[0032] The amino acid sequence boundaries of a CDR can be determined by using any of a number of known numbering schemes, including those described by Kabat et al., supra ("Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 ("Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 ("Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 ("IMGT" numbering scheme); and Honegge and Pluckthun, J. Mol. Biol., 2001, 309:657-70 ("AHo" numbering scheme).
[0033] The term "functional fragment" of an antibody can mean a portion of the antibody which retains a functional activity. A functional activity can be, for example, antigen binding activity or specificity. A functional activity can also be, for example, an effector function provided by an antibody constant region. The term "functional fragment" is also intended to include, for example, fragments produced by protease digestion or reduction of a human monoclonal antibody and by recombinant DNA methods known to those skilled in the art. Human monoclonal antibody functional fragments include, for example individual heavy or light chains and fragments thereof, such as VL, VH and Fd; monovalent fragments, such as Fv, Fab, and Fab'; bivalent fragments such as F(ab')2; single chain Fv (scFv); bivalent or trivalent scFvs, scFv-Fc-scFv, an IgG-scFv, an IgG-dAb, KIH-IgG, KX-BODY, KIH-FC Fab / scFv, tri / tetraspecific, KIH tri / tetra-specific, or a tandem scFv, and Fc fragments. The Fc fragment of the antibody may be disabled by introducing amino acid substitutions into the Fc region, which silence or reduce the effector function of the antibody.
[0034] The term "VL fragment" can mean a fragment of the light chain of a human monoclonal antibody which includes all or part of the light chain variable region, including the CDRs. A VL fragment can further include light chain constant region sequences.
[0035] The term "VH fragment" can mean a fragment of the heavy chain of a human monoclonal antibody which includes all or part of the heavy chain variable region, including the CDRs.
[0036] The term "Fd fragment" can mean the heavy chain variable region coupled to the first heavy chain constant region, i.e. VH and CH-1. The "Fd fragment" does not include the light chain, or the second and third constant regions of the heavy chain.
[0037] The term "Fv fragment" can mean a monovalent antigen-binding fragment of a human monoclonal antibody, including all or part of the variable regions of the heavy and light chains, and absent of the constant regions of the heavy and light chains. The variable regions of the heavy and light chains include, for example, the CDRs. For example, an Fv fragment includes all or part of the amino terminal variable region of about 110 amino acids of both the heavy and light chains.
[0038] The term "Fab fragment" can mean a monovalent antigen-binding fragment of a human monoclonal antibody that is larger than an Fv fragment. For example, a Fab fragment includes the variable regions, and all or part of the first constant domain of the heavy and light chains. Thus, a Fab fragment additionally includes, for example, amino acid residues from about 110 to about 220 of the heavy and light chains.
[0039] The term "Fab' fragment" can mean a monovalent antigen-binding fragment of a human monoclonal antibody that is larger than a Fab fragment. For example, a Fab' fragment includes all of the light chain, all of the variable region of the heavy chain, and all or part of the first and second constant domains of the heavy chain. For example, a Fab' fragment can additionally include some or all of amino acid residues 220 to 330 of the heavy chain.The term "F(ab')2 fragment" can mean a bivalent antigen-binding fragment of a human monoclonal antibody. An F(ab')2 fragment includes, for example, all or part of the variable regions of two heavy chains-and two light chains, and can further include all or part of the first constant domains of two heavy chains and two light chains.
[0040] The term "single chain Fv (scFv)" can mean a fusion of the variable regions of the heavy (VH) and light chains (VL) connected with a short linker peptide.
[0041] One skilled in the art knows that the exact boundaries of a fragment of an antibody are not important, so long as the fragment maintains a functional activity. Using well-known recombinant methods, one skilled in the art can engineer a polynucleotide sequence to express a functional fragment with any endpoints desired for a particular application. A functional fragment of the antibody may comprise or consist of a fragment with substantially the same heavy and light chain variable regions as the human antibody.
[0042] Typically, the antigen-binding fragment thereof, with respect to the first aspect of the invention, are immunospecific for IL-18 or TL1A, or a functional fragment or variant thereof. The antigen-binding fragment thereof may comprise or consist of any of the fragments selected from a group consisting of VH, VL, Fd, Fv, Fab, Fab', scFv, F (ab')2 and Fc fragment.
[0043] The antigen-binding fragment thereof may be a single domain antibody (sdAb), otherwise referred to as a nanobody, which the skilled person would understand is an antibody fragment consisting of a single monomeric variable antibody domain.
[0044] The antigen-binding fragment thereof may comprise or consist of any one of the antigen binding region sequences of the VL, any one of the antigen binding region sequences of the VH, or a combination of VL and VH antigen binding regions of a human antibody. The appropriate number and combination of VH and VL antigen binding region sequences may be determined by those skilled in the art depending on the desired affinity and specificity and the intended use of the antigen-binding fragment. Functional fragments or antigen-binding fragments of antibodies may be readily produced and isolated using methods well known to those skilled in the art. Such methods include, for example, proteolytic methods, recombinant methods and chemical synthesis. Proteolytic methods for the isolation of functional fragments comprise using human antibodies as a starting material. Enzymes suitable for proteolysis of human immunoglobulins may include, for example, papain, and pepsin.The appropriate enzyme may be readily chosen by one skilled in the art, depending on, for example, whether monovalent or bivalent fragments are required. For example, papain cleavage results in two monovalent Fab' fragments that bind antigen and an Fc fragment. Pepsin cleavage, for example, results in a bivalent F (ab') fragment. An F (ab')2 fragment of the invention may be further reduced using, for example, DTT or 2-mercaptoethanol to produce two monovalent Fab' fragments.
[0045] Functional or antigen-binding fragments of antibodies produced by proteolysis may be purified by affinity and column chromatographic procedures. For example, undigested antibodies and Fc fragments may be removed by binding to protein A. Additionally, functional fragments may be purified by virtue of their charge and size, using, for example, ion exchange and gel filtration chromatography. Such methods are well known to those skilled in the art.
[0046] The antibody or antigen-binding fragment thereof may be produced by recombinant methodology. In some embodiments, one initially isolates a polynucleotide encoding desired regions of the antibody heavy and light chains. Such regions may include, for example, all or part of the variable region of the heavy and light chains. In some embodiments, such regions can particularly include the antigen binding regions of the heavy and light chains, typically the antigen binding sites, most typically the CDRs.
[0047] The polynucleotide encoding the bispecific antibody or antigen-binding fragment thereof according to the invention may be produced using methods known to those skilled in the art. The polynucleotide encoding the bispecific antibody or antigenbinding fragment thereof may be directly synthesized by methods of oligonucleotide synthesis known in the art. Alternatively, smaller fragments may be synthesized and joined to form a larger functional fragment using recombinant methods known in the art.
[0048] As used herein, the term "immunospecificity" can mean the binding region of the bispecific antibody or antigen-binding fragment thereof is capable of immunoreacting with IL-18 and TL1A, by specifically binding therewith. In some embodiments, the bispecific antibody or antigen-binding fragment thereof can selectively interact with an antigen (i.e. IL-18 and TL1A) with an affinity constant of approximately 10'5to 10'13M’1, or IO’6to IO’9M’1, or IO’10to IO’12M’1.The term "immunoreact" can mean the binding region is capable of eliciting an immune response upon binding with IL-18 and TL1A, or an epitope thereof.
[0049] The term "epitope" can mean any region of an antigen with the ability to elicit, and combine with, a binding region of the bispecific antibody or antigen-binding fragment thereof. The epitope may be linear. This can mean that the antibody interacts with a plurality of continuous amino acids of the antigen, and so the epitope can consist of these defined amino acids. Alternatively, the epitope may be conformational, i.e. nonlinear or discontinuous. This can mean that the antibody interacts with multiple, distinct segments from the primary amino acid sequence of the antigen.
[0050] Thus, the bispecific antibody or antigen-binding fragment thereof may comprise a heavy chain. The heavy chain may be selected from the group consisting of IgA; IgD; IgE; IgG and IgM. In some embodiments, the heavy chain is an IgA. In some embodiments, the heavy chain is an IgG.
[0051] The heavy chain may be an IgGl. The heavy chain may be an IgG2. The heavy chain may be an IgG3. The heavy chain may be an IgG4. The heavy chain may be an IgAl. The heavy chain may be an IgA2.
[0052] In some embodiments, the bispecific antibody is a heterodimeric antibody. In some embodiments, the bispecific antibody is derived from two monoclonal antibodies (mAbs), an anti-IL-18 mAb or antigen-binding fragment thereof, and an anti-TLIA mAb or antigen-binding fragment thereof. In some embodiments, the anti-IL-18 mAb or antigen-binding fragment thereof contributes to the first antigen-binding domain binding to IL-18 in the bispecific antibody. In some embodiments, the anti-TLIA mAb or antigen-binding fragment thereof contributes to the second antigen-binding domain binding to TL1A in the bispecific antibody. In some embodiments, each of these mAbs contributes one distinct heavy (H) chain and one distinct light (L) chain to the bispecific antibody, resulting in four chains in the bispecific antibody. In some embodiments, the four chains in the bispecific antibody are covalently linked via five inter-chain disulfide bonds.
[0053] In some embodiments, the bispecific antibody comprises: a) a first antigen-binding domain comprising a first light chain variable domain (VL1) and a first heavy chain variable domain (VH1), that binds specifically to IL-18 or a functional fragment or variant thereof, and b) a second antigen-binding domain comprising a second lightchain variable domain (VL2) and a second heavy chain variable domain (VH2), that binds specifically to TL1A or a functional fragment or variant thereof.
[0054] In some embodiments, the first antigen-binding domain comprises an IL-18 scFv or an IL-18 Fab. In some embodiments, the first antigen-binding domain comprises one or two IL-18 Fabs.
[0055] In some embodiments, the second antigen-binding domain comprises a TL1A scFv or a TL1A Fab. In some embodiments, the second antigen-binding domain comprises one or two TL1A Fabs.
[0056] In some embodiments, the first antigen-binding domain comprises an IL-18 scFv and the second antigen-binding domain comprises an TL1A scFv. In some embodiments, the two scFv are linked to each other by a shorter linked peptide.
[0057] In some embodiments, the first and second antigen-binding domains of the bispecific antibody or antigen-binding fragment thereof are linked. In some embodiments, that linkage is a direct linkage, and the regions are fused to each other. In some embodiments, the first binding domain and / or the second binding domain are fused to a Fc polypeptide chain. In some embodiments, the second binding domain (e.g. TL1A Fab) is linked, e.g., via a polypeptide linker, to the N-terminus of the first binding domain. In some embodiments, the second binding domain (e.g. TL1A Fab) is linked, e.g., fused, to the N-terminus of the first binding domain.
[0058] Protocols for generating bispecific antibodies are known in the art; including but not limited to, for example, the "knob in a hole" approach; the electrostatic steering Fc pairing; Strand Exchange Engineered Domains (SEED) heterodimer formation; Fab arm exchange; double antibody conjugate, e.g., by antibody cross-linking to generate a bi-specific structure using a heterobifunctional reagent having an amine-reactive group and a sulfhydryl reactive group; bispecific antibody or antibody-like molecule determinants generated by recombining half antibodies (heavy-light chain pairs or Fabs) from different antibodies or antibody-like molecules through cycle of reduction and oxidation of disulfide bonds between the two heavy chains; trifunctional antibodies, e.g., three Fab' fragments cross-linked through sulfhydryl reactive groups; biosynthetic binding proteins, e.g., pair of scFvs cross-linked through C-terminal tails preferably through disulfide or amine-reactive chemical cross-linking; bifunctional antibodies, e.g., Fab fragments with different binding specificities dimerized through leucine zippers that have replaced the constant domain; bispecific and oligospecificmono-and oligovalent receptors, e.g., VH-CH1 regions of two antibodies (two Fab fragments) linked through a polypeptide spacer between the CHI region of one antibody and the VH region of the other antibody typically with associated light chains; bispecific DNA-antibody conjugates, e.g., crosslinking of antibodies or Fab fragments through a double stranded piece of DNA; bispecific fusion proteins, e.g., an expression construct containing two scFvs with a hydrophilic helical peptide linker between them and a full constant region; multivalent and multi-specific binding proteins, e.g., dimer of polypeptides having first domain with binding region of Ig heavy chain variable region, and second domain with binding region of Ig light chain variable region, generally termed diabodies (higher order structures are also encompassed creating for bispecific, trispecific, or tetraspecific molecules; minibody constructs with linked VL and VH chains further connected with peptide spacers to an antibody hinge region and CH3 region, which can be dimerized to form bispecific / multivalent molecules; VL and VH domains linked with a short peptide linker (e.g., 5 or 10 amino acids) or no linker at all in either orientation, which can form dimers to form bispecific diabodies; trimers and tetramers; string of VH domains (or VL domains in family members) connected by peptide linkages with crosslinkable groups at the C-terminus further associated with VL domains to form a series of Fvs (or scFvs); VL and VH domains, scFvs, or Fabs wherein one of the antigens is bound monovalently and one of the antigens is bound bivalently, optionally comprising heterodimeric Fc regions; and single chain binding polypeptides with both a VL and VH domain linked through a peptide linker are combined into multivalent structures through non-covalent or chemical crosslinking to form, e.g., homobivalent, heterobivalent, trivalent, and tetravalent structures using both scFv or diabody type format.
[0059] Controlled Fab-arm exchange (cFAE) is the in vitro post-production process in which IgGl half-molecules recombine with other IgGl half-molecules to generate bispecific IgGl antibodies. In particular, this involves the recombination of antigen-binding arms (heavy chain-light chain (H-L) pairs) between individually expressed antibody molecules. This unidirectional reaction takes place under tailored reaction conditions in vitro with IgGl antibodies containing single matched point-mutations in the CH3 domains. To promote Fc heterodimerization, one antibody is engineered with an F405L mutation and the other with a K409R mutation. The two parental antibodies are expressed separately, mixed at equimolar ratios, and subjected to mild reducing conditions to allow Fab-arm exchange. Upon removal of the reducing agent, interheavy chain disulfide bonds reform, stabilizing the heterodimeric bispecific antibody.The DuoBody® biotechnology involves three basic steps to generate stable bispecific human IgGl antibodies. In a first step, two IgGls, each containing single matched mutations in the third constant (CH3) domain (lysine at position 409 to arginine, K409R; phenylalanine at position 405 to leucine, F405L), are produced separately using recombinant mammalian expression systems. These mutations allow the homodimeric, monospecific parental mAbs against different targets to recombine to form a single heterodimeric, bispecific antibody. Subsequently, these IgGl antibodies are purified according to standard processes for recovery and purification. After production and purification (post-production), the two antibodies are recombined using controlled Fab-arm exchange (cFAE), resulting in a bispecific antibody product.
[0060] The basis of the CrossMab technology is the crossover of antibody domains within one arm of a bispecific IgG antibody enabling correct chain association. This can be achieved by exchange of different domains within the Fab-fragment. Either the Fab domains (in the CrossMabFabformat), or only the variable VH-VL domains (CrossMabVH‘VLformat) or the constant CH1-CL domains (CrossMabCH1'CLformat) within the Fab-fragment can be exchanged for this purpose. For example, the Fab arm retains a conventional heavy chain / light chain pairing, and the second arm contains variable domains which have been swapped at the molecular level to promote correct chain pairing. The Fc is engineered for heterodimerization with one arm using a 'knob' mutation (T366W) and 'hole' mutations (T366S, L368A, Y407V) on the other arm.
[0061] WuxiBody technology involves the replacement of one parental mAb's CH1 / CL region by the T cell receptor (TOR) constant domain. WuXiBody's design ensures cognate HC-LC pairing, the same goal as that being aimed by the CrossMab technology. One Fab arm comprises immunoglobulin (IgG) constant domains and the other Fab arm comprises engineered human TCR constant domains (Co / CP), enabling orthogonal heavy / light chain pairing. The Fc is engineered for heterodimerization with one arm using a 'knob' mutation (T366W) and 'hole' mutations (T366S, L368A, Y407V) on the other arm.
[0062] Mispairing and mismatching between light chains and heavy chains can occur when preparing the bispecific antibody or antigen binding fragment thereof. Mispairing refers to the incorrect pairing of heavy and light chains during antibody assembly. Mismatching refers to the presence of different types of antibody chains within a bispecific antibody, even if the chains are correctly paired. This can occur due to genetic or structural variability within the antibody chains, leading to a broaderspectrum of antibody species. Antibodies with mispairing and / or mismatches may have to be separated from the desired bispecific antibodies by purification processes.
[0063] In one embodiment, the amino acid sequence of IL-18 may be provided herein as SEQ ID No: 42, as follows:
[0064] MAAEPVEDNCINFVAMKFIDNTLYFIAEDDENLESDYFGKLESKLSVIRNLNDQVLFIDQGNRPLFEDMTDSDCRDNAPRT IFI ISMYKDSQPRGMAVTI SVKCEKISTLSCENKI ISFKEMNPPDNIKDTKSDI IFFQRSVPGHDNKMQFESSSYEGYFLA CEKERDLFKLI LKKEDELGDRS IMFTVQNED
[0065] [SEQ ID No: 42]
[0066] Thus, in one embodiment, the bispecific antibody or antigen-binding fragment thereof binds to one or more amino acids within a sequence comprising or consisting of a sequence as substantially set out in SEQ ID No: 42, or a functional fragment or variant thereof.
[0067] In one embodiment, the amino acid sequence of TL1A may be provided herein as SEQ ID No: 43, as follows:
[0068] MAEDLGLSFGETASVEMLPEHGSCRPKARSSSARWALTCCLVLLPFLAGLTTYLLVSQLRAQGEACVQFQALKGQEFAPSH QQVYAPLRADGDKPRAHLTWRQTPTQHFKNQFPALHWEHELGLAFTKNRMNYTNKFLLIPESGDYFIYSQVTFRGMTSEC SEIRQAGRPNKPDSITVVITKVTDSYPEPTQLLMGTKSVCEVGSNWFQPIYLGAMFSLQEGDKLMVNVSDISLVDYTKEDK TFFGAFLL
[0069] [SEQ ID No: 43]
[0070] Thus, in one embodiment, the bispecific antibody or antigen-binding fragment thereof binds to one or more amino acids within a sequence comprising or consisting of a sequence as substantially set out in SEQ ID No: 43, or a functional fragment or variant thereof.
[0071] It will be appreciated that "functional fragment or variant thereof" refers to fragments and variants of IL-18 and / or TL1A that retain at least part of the activity of IL-18 and / or TL1A.
[0072] As described in the Examples, the inventors have surprisingly demonstrated that the bispecific antibodies or antigen-binding fragments referred to herein, are able to significantly target IL-18 and TL1A, or functional fragments or variants thereof, and each of these antibodies are defined below in detail. The CDR, VH, VL, CH and CL sequences of these antibodies are conveniently summarised in the table shown in Figure 1. The sequences are provided using Kabat, Chothia, IMGT and Combined numbering schemes.
[0073]
[0074] Al-Bl
[0075] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as Al-Bl.
[0076] First antigen-binding domain (IL-18)
[0077] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.
[0078] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.
[0079] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.
[0080] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0081] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.
[0082] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.
[0083] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.
[0084] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.
[0085] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0086] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0087] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.
[0088] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0089] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, aCDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0090] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0091] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0092] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0093] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15.
[0094] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 17, or a variant or fragment thereof.
[0095] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 17 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0096] Second antigen-binding domain (TL1A)
[0097] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27 , 29 or 32, or a variant or fragment thereof.
[0098] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.
[0099] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.
[0100] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.
[0101] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.
[0102] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.
[0103] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.
[0104] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.
[0105] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0106] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0107] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.
[0108] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0109] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0110] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0111] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0112] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0113] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0114] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
[0115] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 41, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0116] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 41 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0117] A2-B2 (IL-18 CrossMab Regular Arm / TLIA CrossMab Cross Arm)
[0118] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A2-B2.
[0119] First antigen-binding domain (IL-18)
[0120] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.
[0121] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.
[0122] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.
[0123] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0124] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domaincomprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.
[0125] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.
[0126] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.
[0127] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.
[0128] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.
[0129] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0130] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0131] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0132] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0133] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0134] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0135] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0136] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.
[0137] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0138] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0139] Second antigen-binding domain (TL1A)
[0140] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.
[0141] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.
[0142] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.
[0143] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 or 37 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 35.
[0144] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 37 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 35.In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.
[0145] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27 , 29 or 32, or a variant or fragment thereof.
[0146] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.
[0147] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.
[0148] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 26 or 31.
[0149] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 24, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 27 , a CDR-L2 domain comprising or consisting of SEQ ID No: 28, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 29, a CDR-L2 domain comprising or consisting of SEQ ID No: 30, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 31.
[0150] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0151] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 or 37, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 24, 27, 29 or 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26 or 31.
[0152] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 24, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26.
[0153] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 27 , a CDR-L2 domain comprising or consisting of SEQ ID No: 28, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26.
[0154] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 37, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 29, a CDR-L2 domain comprising or consisting of SEQ ID No: 30, and a CDR-L3 domain comprising or consisting of SEQ ID No: 31.
[0155] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 32, a CDR-L2 domaincomprising or consisting of SEQ ID No: 25, and a CDR-L3 domain comprising or consisting of SEQ ID No: 31.
[0156] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 39, and a light chain variable region comprising or consisting of SEQ ID No: 38.
[0157] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 19, or a variant or fragment thereof.
[0158] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 22, or a variant or fragment thereof.
[0159] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 19 and a light chain constant region comprising or consisting of SEQ ID No: 22.
[0160] A3-B3 (IL-18 CrossMab Cross Arm / TL1A CrossMab Regular Arm)
[0161] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A3-B3.
[0162] First antigen-binding domain (IL-18)
[0163] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.
[0164] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.
[0165] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.
[0166] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-H2 domain comprising orconsisting of SEQ ID No: 10 or 13 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 11.
[0167] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9, a CDR-H2 domain comprising or consisting of SEQ ID No: 10 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 13 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 11.
[0168] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.
[0169] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.
[0170] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.
[0171] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.
[0172] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0173] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 1, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 4, a CDR-L2 domain comprising or consisting of SEQ ID No: 5, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domaincomprising or consisting of SEQ ID No: 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 7, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 8.
[0174] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.
[0175] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0176] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 10 or 13, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0177] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9, a CDR-H2 domain comprising or consisting of SEQ ID No: 10, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 1, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3.
[0178] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9, a CDR-H2 domain comprising or consisting of SEQ ID No: 10, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 4, a CDR-L2 domain comprising or consisting of SEQ ID No: 5, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3.
[0179] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 13, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 7, and a CDR-L3 domain comprising or consisting of SEQ ID No: 8.In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 15, and a light chain variable region comprising or consisting of SEQ ID No: 14.
[0180] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 19, or a variant or fragment thereof.
[0181] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 22, or a variant or fragment thereof.
[0182] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 19 and a light chain constant region comprising or consisting of SEQ ID No: 22.
[0183] Second antigen-binding domain (TL1A)
[0184] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27 , 29 or 32, or a variant or fragment thereof.
[0185] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.
[0186] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.
[0187] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.
[0188] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.
[0189] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.
[0190] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.
[0191] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.
[0192] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.
[0193] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0194] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.
[0195] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0196] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0197] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0198] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0199] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0200] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
[0201] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.
[0202] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0203] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0204] A4-B4 (IL-18 WuxiBodv Regular Arm / TL1A WuxiBodv Wuxi Arm)
[0205] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A4-B4.
[0206] First antigen-binding domain (IL-18)
[0207] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.
[0208] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.
[0209] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0210] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.
[0211] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.
[0212] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.
[0213] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.
[0214] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.
[0215] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising orconsisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0216] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0217] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.
[0218] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0219] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0220] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0221] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising orconsisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0222] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0223] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15.
[0224] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.
[0225] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0226] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0227] Second antigen-binding domain (TL1A)
[0228] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27 , 29 or 32, or a variant or fragment thereof.
[0229] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.
[0230] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.
[0231] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.
[0232] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 40, or a variant or fragment thereof.
[0233] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.
[0234] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.
[0235] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.
[0236] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising orconsisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0237] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0238] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.
[0239] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0240] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0241] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0242] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domaincomprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0243] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0244] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0245] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 40, and a light chain variable region comprising or consisting of SEQ ID No: 39.
[0246] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 20, or a variant or fragment thereof.
[0247] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 23, or a variant or fragment thereof.
[0248] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 20 and a light chain constant region comprising or consisting of SEQ ID No: 23.
[0249] A5-B5 (IL-18 WuxiBodv Wuxi Arm / TL1A WuxiBodv Regular Arm)
[0250] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A5-B5.
[0251] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.
[0252] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.
[0253] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.
[0254] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0255] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.
[0256] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 16, or a variant or fragment thereof.
[0257] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.
[0258] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.
[0259] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0260] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0261] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.
[0262] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0263] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0264] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising orconsisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0265] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0266] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0267] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 16, and a light chain variable region comprising or consisting of SEQ ID No: 15.
[0268] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 20, or a variant or fragment thereof.
[0269] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 23, or a variant or fragment thereof.
[0270] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 20 and a light chain constant region comprising or consisting of SEQ ID No: 23.
[0271] Second antigen-binding domain (TL1A)
[0272] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27 , 29 or 32, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.
[0273] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.
[0274] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.
[0275] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.
[0276] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.
[0277] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.
[0278] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.
[0279] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0280] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0281] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.
[0282] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0283] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0284] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0285] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0286] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0287] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
[0288] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.
[0289] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0290] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains consisting of heavy chain variable regions comprising CDR1, CDR2, and CDR3 sequences and light chain variable regions comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 1, 4, 6, 9, 12, 24, 27, 29, 32, 33 and 36, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 2, 5, 7, 10, 13, 25, 28, 30, 34 and 37, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 3, 8, 11, 26, 31 and 35, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 9, 12, 1, 4, 6, 33, 36, 24, 27 , 29 and 32, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 10, 13, 2, 5, 7, 34, 37, 25, 28 and 30, or variant sequences thereof comprising 1 , 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions of CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 11, 3, 8, 35, 26 and 31, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof.
[0291] In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 15, 16, 38, 39 and 40; the light chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 15, 14, 39 and 38. Alternatively the bispecific antibody or antigen-binding fragment thereof comprises first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequenceselected from the group consisting of SEQ ID NOs: 14, 15, 16, 38, 39 and 40; the light chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 15, 14, 39 and 38. In this context, the term "change" refers to insertions, deletions and / or substitutions.
[0292] The antibody of the invention may comprise or consist of any sequence as defined in Figure 12.
[0293] bsAb 1
[0294] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 1. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0295] First antigen-binding domain (IL-18)
[0296] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0297] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0298] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0299] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0300] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0301] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0302] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0303] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0304] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0305] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0306] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0307] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.
[0308] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0309] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0310] Second antigen-binding domain (TL1A)
[0311] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0312] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0313] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0314] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0315] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0316] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0317] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0318] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0319] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0320] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0321] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0322] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0323] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0324] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0325] bsAb 3
[0326] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 3. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-TLIA cross, with knob on cross arm (orientation 1 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0327] First antigen-binding domain (IL-18)
[0328] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0329] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0330] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0331] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0332] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0333] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0334] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0335] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0336] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0337] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0338] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0339] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[0340] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0341] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0342] Second antigen-binding domain (TL1A)
[0343] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0344] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0345] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0346] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 120 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 121.
[0347] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0348] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0349] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0350] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 116.
[0351] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0352] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0353] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 120, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 116.
[0354] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 122, and a light chain variable region comprising or consisting of SEQ ID No: 117.
[0355] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0356] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0357] bsAb 4
[0358] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 4. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-TLIA cross, with hole on cross arm (orientation 2 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0359] First antigen-binding domain (IL-18)
[0360] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0361] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0362] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0363] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0364] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0365] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0366] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0367] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0368] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0369] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0370] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0371] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.
[0372] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0373] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 127 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0374] Second antigen-binding domain (TL1A)
[0375] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0376] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0377] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0378] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 120 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 121.
[0379] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0380] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0381] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0382] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 116.
[0383] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0384] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0385] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 120, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 116.
[0386] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 122, and a light chain variable region comprising or consisting of SEQ ID No: 117.
[0387] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0388] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 126 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0389] bsAb 5
[0390] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 5. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with hole on cross arm (orientation 4 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0391] First antigen-binding domain (IL-18)
[0392] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0393] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0394] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0395] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0396] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0397] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0398] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0399] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0400] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0401] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0402] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0403] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.
[0404] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0405] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 126 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0406] Second antigen-binding domain (TL1A)
[0407] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0408] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0409] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0410] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0411] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0412] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0413] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0414] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0415] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0416] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0417] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0418] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0419] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0420] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 127 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0421] bsAb 7
[0422] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 7. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab CH-CL anti-TLIA cross, with knob on cross arm (orientation 5 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0423] First antigen-binding domain (IL-18)
[0424] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0425] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0426] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0427] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0428] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0429] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0430] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0431] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0432] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0433] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0434] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0435] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[0436] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0437] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0438] Second antigen-binding domain (TL1A)
[0439] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0440] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0441] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0442] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0443] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0444] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0445] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0446] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0447] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0448] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0449] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0450] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0451] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.
[0452] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 128 and a light chain constant region comprising or consisting of SEQ ID No: 129.
[0453] bsAb 6
[0454] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 6. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab CH-CL anti-TLIA cross, with hole on cross arm (orientation 6 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0455] First antigen-binding domain (IL-18)
[0456] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0457] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0458] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0459] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0460] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0461] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0462] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0463] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0464] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0465] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0466] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0467] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 131, or a variant or fragment thereof.
[0468] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0469] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 131 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0470] Second antigen-binding domain (TL1A)
[0471] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0472] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0473] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0474] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0475] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0476] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0477] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0478] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0479] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0480] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0481] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0482] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0483] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 130, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.
[0484] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 130 and a light chain constant region comprising or consisting of SEQ ID No: 129.
[0485] bsAb 2
[0486] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 2. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab CH-CL anti-IL-18 cross, with knob on cross arm (orientation 7 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0487] First antigen-binding domain (IL-18)
[0488] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0489] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0490] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0491] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0492] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0493] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0494] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0495] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0496] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0497] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0498] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0499] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.
[0500] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.
[0501] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 128 and a light chain constant region comprising or consisting of SEQ ID No: 129.
[0502] Second antigen-binding domain (TL1A)
[0503] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0504] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0505] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0506] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0507] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0508] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0509] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0510] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0511] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0512] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0513] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0514] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0515] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0516] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0517] bsAb 8
[0518] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 8. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab CH-CL anti-IL-18 cross, with hole on cross arm (orientation 8 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0519] First antigen-binding domain (IL-18)
[0520] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0521] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0522] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0523] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0524] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0525] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0526] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0527] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0528] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0529] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0530] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0531] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 130, or a variant or fragment thereof.
[0532] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.
[0533] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 130 and a light chain constant region comprising or consisting of SEQ ID No: 129.
[0534] Second antigen-binding domain (TL1A)
[0535] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0536] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0537] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0538] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0539] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0540] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0541] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0542] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0543] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0544] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0545] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0546] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0547] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0548] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 127 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0549] bsAb 9
[0550] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 9. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.
[0551] First antigen-binding domain (IL-18)
[0552] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0553] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0554] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0555] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0556] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0557] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0558] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0559] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0560] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0561] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0562] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0563] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 133, or a variant or fragment thereof.
[0564] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0565] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 133 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0566] Second antigen-binding domain (TL1A)
[0567] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0568] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0569] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0570] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0571] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0572] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0573] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0574] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0575] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0576] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0577] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0578] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0579] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0580] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 132 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0581] bsAb 10
[0582] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 10. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LALA YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234A and L235A and / or M252Y, S254T, and T256E.
[0583] First antigen-binding domain (IL-18)
[0584] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0585] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0586] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0587] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0588] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0589] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0590] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0591] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0592] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0593] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0594] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0595] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 135, or a variant or fragment thereof.
[0596] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0597] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 135 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0598] Second antigen-binding domain (TL1A)
[0599] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0600] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0601] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0602] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0603] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0604] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0605] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0606] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0607] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0608] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0609] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0610] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0611] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 134, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0612] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 134 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0613] bsAb 11
[0614] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 11. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LALA LS mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234A and L235A and / or M428L and N434S.
[0615] First antigen-binding domain (IL-18)
[0616] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0617] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0618] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0619] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0620] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0621] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0622] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0623] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0624] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0625] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0626] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0627] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 137, or a variant or fragment thereof.
[0628] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0629] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 137 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0630] Second antigen-binding domain (TL1A)
[0631] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0632] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0633] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0634] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0635] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0636] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0637] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0638] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0639] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0640] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0641] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0642] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0643] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0644] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 136 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0645] bsAb 12
[0646] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 12. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES LS mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M428L and N434S.
[0647] First antigen-binding domain (IL-18)
[0648] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0649] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0650] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0651] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0652] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0653] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0654] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0655] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0656] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0657] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0658] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0659] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 139, or a variant or fragment thereof.
[0660] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0661] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 139 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0662] Second antigen-binding domain (TL1A)
[0663] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0664] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0665] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0666] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0667] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0668] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0669] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0670] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0671] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0672] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0673] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0674] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0675] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 138, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0676] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 138 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0677] bsAb 13
[0678] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 13. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S. Alternatively, in other embodiments, the antibody may be an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with hole on cross arm.
[0679] First antigen-binding domain (IL-18)
[0680] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0681] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0682] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0683] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0684] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0685] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0686] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0687] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0688] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0689] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0690] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0691] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.
[0692] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0693] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0694] Second antigen-binding domain (TL1A)
[0695] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 249, or a variant or fragment thereof.
[0696] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 250, or a variant or fragment thereof.
[0697] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 251, or a variant or fragment thereof.
[0698] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 249, a CDR-H2 domain comprising or consisting of SEQ ID No: 250 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 251.
[0699] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 140, or a variant or fragment thereof.
[0700] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 142, or a variant or fragment thereof.
[0701] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 143, or a variant or fragment thereof.
[0702] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 141, a CDR-L2 domain comprising or consisting of SEQ ID No: 142, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 143.
[0703] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 144, or a variant or fragment thereof.
[0704] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0705] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 249, a CDR-H2 domain comprising or consisting of SEQ ID No: 250, a CDR-H3 domain comprising or consisting of SEQ ID No: 251, a CDR-L1 domain comprising or consisting of SEQ ID No: 141, a CDR-L2 domain comprising or consisting of SEQ ID No: 142, and a CDR-L3 domain comprising or consisting of SEQ ID No: 143.
[0706] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 140, and a light chain variable region comprising or consisting of SEQ ID No: 144.
[0707] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 145, or a variant or fragment thereof.
[0708] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 145.
[0709] bsAb 14
[0710] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 14. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab CH-CL anti-IL-18 cross, with knob on cross arm (orientation 7 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S. Alternatively, in other embodiments, the antibody may be an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with hole on cross arm.
[0711] First antigen-binding domain (IL-18)
[0712] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0713] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0714] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0715] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0716] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0717] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0718] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0719] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0720] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0721] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0722] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0723] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.
[0724] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.
[0725] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 128 and a light chain constant region comprising or consisting of SEQ ID No: 129.
[0726] Second antigen-binding domain (TL1A)
[0727] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 249, or a variant or fragment thereof.
[0728] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 250, or a variant or fragment thereof.
[0729] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 251, or a variant or fragment thereof.
[0730] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 249, a CDR-H2 domain comprising or consisting of SEQ ID No: 250 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 251.
[0731] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 140, or a variant or fragment thereof.
[0732] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 142, or a variant or fragment thereof.
[0733] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 143, or a variant or fragment thereof.
[0734] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 141, a CDR-L2 domain comprising or consisting of SEQ ID No: 142, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 143.
[0735] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 144, or a variant or fragment thereof.
[0736] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0737] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 249, a CDR-H2 domain comprising or consisting of SEQ ID No: 250, a CDR-H3 domain comprising or consisting of SEQ ID No: 251, a CDR-L1 domain comprising or consisting of SEQ ID No: 141, a CDR-L2 domain comprising or consisting of SEQ ID No: 142, and a CDR-L3 domain comprising or consisting of SEQ ID No: 143.
[0738] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 140, and a light chain variable region comprising or consisting of SEQ ID No: 144.
[0739] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 145, or a variant or fragment thereof.
[0740] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 145.
[0741] bsAb 15
[0742] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 15. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-TLIA cross, with knob on cross arm (orientation 1 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S. Alternatively, in other embodiments, the antibody may be an anti-IL-18xTLlA CrossMab VH-VL anti-IL-TL1A cross, with hole on cross arm.
[0743] First antigen-binding domain (IL-18)
[0744] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0745] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0746] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0747] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0748] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0749] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0750] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0751] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0752] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0753] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0754] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0755] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[0756] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0757] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0758] Second antigen-binding domain (TL1A)
[0759] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.
[0760] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 142, or a variant or fragment thereof.
[0761] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 143, or a variant or fragment thereof.
[0762] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 141, a CDR-H2 domain comprising or consisting of SEQ ID No: 142 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 143.
[0763] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 144, or a variant or fragment thereof.
[0764] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 249, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 250, or a variant or fragment thereof.
[0765] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 251, or a variant or fragment thereof.
[0766] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 249, a CDR-L2 domain comprising or consisting of SEQ ID No: 250, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 251.
[0767] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 140, or a variant or fragment thereof.
[0768] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0769] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 141, a CDR-H2 domain comprising or consisting of SEQ ID No: 142, a CDR-H3 domain comprising or consisting of SEQ ID No: 143, a CDR-L1 domain comprising or consisting of SEQ ID No: 249, a CDR-L2 domain comprising or consisting of SEQ ID No: 250, and a CDR-L3 domain comprising or consisting of SEQ ID No: 251.
[0770] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 144, and a light chain variable region comprising or consisting of SEQ ID No: 140.
[0771] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0772] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0773] bsAb 16
[0774] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 16. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab CH-CL anti-TLIA cross, with knob on cross arm (orientation 5 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S. Alternatively, in other embodiments, the antibody may be an anti-IL-18xTLlA CrossMab CH-CL anti-IL-TL1A cross, with hole on cross arm.
[0775] First antigen-binding domain (IL-18)
[0776] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0777] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0778] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0779] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0780] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0781] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0782] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0783] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0784] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0785] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0786] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0787] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[0788] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0789] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0790] Second antigen-binding domain (TL1A)
[0791] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 249, or a variant or fragment thereof.
[0792] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 250, or a variant or fragment thereof.
[0793] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 251, or a variant or fragment thereof.
[0794] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 249, a CDR-H2 domain comprising or consisting of SEQ ID No: 250 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 251.
[0795] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 140, or a variant or fragment thereof.
[0796] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 142, or a variant or fragment thereof.
[0797] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 143, or a variant or fragment thereof.
[0798] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 141, a CDR-L2 domain comprising or consisting of SEQ ID No: 142, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 143.
[0799] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 144, or a variant or fragment thereof.
[0800] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0801] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 249, a CDR-H2 domain comprising or consisting of SEQ ID No: 250, a CDR-H3 domain comprising or consisting of SEQ ID No: 251, a CDR-L1 domain comprising or consisting of SEQ ID No: 141, a CDR-L2 domain comprising or consisting of SEQ ID No: 142, and a CDR-L3 domain comprising or consisting of SEQ ID No: 143.
[0802] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 140, and a light chain variable region comprising or consisting of SEQ ID No: 144.
[0803] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.
[0804] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 128 and a light chain constant region comprising or consisting of SEQ ID No: 129.
[0805] In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains consisting of heavy chain variable regions comprising CDR1, CDR2, and CDR3 sequences and light chain variable regions comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 119, 44, 114, 49, 141 and 249, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 120, 45, 115, 50, 142 and 250, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 121, 46, 116, 51, 46, 143 and 251, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 114, 49, 119, 44, 141 and 249, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 115, 50, 120, 45, 142 and 250, or variant sequences thereof comprising 1 , 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions of CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 116, 51, 121, 46, 143 and 251, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof.
[0806] In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 122, 47, 117, 52, 140 and 144;the light chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 117, 52, 122, 47, 144 and 140. Alternatively the bispecific antibody or antigen-binding fragment thereof comprises first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 122, 47, 117, 52, 140 and 144; the light chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 117, 52, 122, 47, 144 and 140. In this context, the term "change" refers to insertions, deletions and / or substitutions.
[0807] The antibody of the invention may comprise or consist of any sequence as defined in Figure 16.
[0808] Affinity matured variants
[0809] As described in the Examples, the inventors have subjected a parent IL-18 antibody and a parent TL1A antibody to affinity maturation in order to produce novel variants or mutants, with improved activity. The six CDR, VH, VL, CH and CL sequences of the affinity matured antibodies are summarised in the tables shown in Figure 14 (IL-18 affinity matured variants) and Figure 15 (TL1A affinity matured variants).
[0810] Accordingly, in some embodiments, the first antigen-binding domain comprises any sequence as defined in Figure 14, and the second antigen-binding domain comprises any sequence as defined in Figure 15. For example, it will be appreciated that the IL- 18 arm ("IL-18 mAbl", or "IL-18 mAb2", etc.) shown in Figure 14, may be combined with any of the TL1A arms shown in Figure 15, such as ""TL1A mAb 1" or "TL1A mAb 10", etc.
[0811] In some embodiments, the first antigen-binding domain comprises any of the heavy and light chain CDR sequences as defined in Figure 14. In some embodiments, the first antigen-binding domain comprises any of the heavy and light chain variable sequences as defined in Figure 14. In some embodiments, the first antigen-binding domain comprises any of the heavy and light chain constant sequences as defined in Figure 14.In some embodiments, the second antigen-binding domain comprises any of the heavy and light chain CDR sequences as defined in Figure 15. In some embodiments, the second antigen-binding domain comprises any of the heavy and light chain variable sequences as defined in Figure 15. In some embodiments, the second antigen-binding domain comprises any of the heavy and light chain constant sequences as defined in Figure 15.
[0812] Figure 17 is a table showing the six CDR, VH, VL, CH and CL sequences of the first (IL-18) and second (TL1A) antigen-binding domains of the affinity matured bispecific antibodies according to the invention. Accordingly, in some embodiments, the first and second antigen-binding domains comprise any of the heavy and light chain CDR sequences, any of the heavy and light chain variable sequences, and / or any of the heavy and light chain constant sequences, as defined in Figure 17.
[0813] bsAb 17
[0814] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 17. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0815] First antigen-binding domain (IL-18)
[0816] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0817] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0818] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0819] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0820] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0821] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0822] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0823] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0824] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0825] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0826] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domaincomprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0827] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0828] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.
[0829] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0830] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0831] Second antigen-binding domain (TL1A)
[0832] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0833] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 220, or a variant or fragment thereof.
[0834] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0835] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 221, or a variant or fragment thereof.
[0836] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0837] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0838] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0839] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0840] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0841] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0842] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 221, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0843] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[0844] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0845] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0846] bsAb 18
[0847] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 18. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0848] First antigen-binding domain (IL-18)
[0849] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0850] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0851] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0852] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0853] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0854] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0855] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0856] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0857] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0858] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0859] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domaincomprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0860] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0861] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.
[0862] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0863] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0864] Second antigen-binding domain (TL1A)
[0865] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0866] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 220, or a variant or fragment thereof.
[0867] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 222, or a variant or fragment thereof.
[0868] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 222.In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 223, or a variant or fragment thereof.
[0869] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0870] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 224, or a variant or fragment thereof.
[0871] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0872] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0873] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 225, or a variant or fragment thereof.
[0874] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0875] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220, a CDR-H3 domain comprising or consisting of SEQ ID No: 222, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 223, and a light chain variable region comprising or consisting of SEQ ID No: 225.
[0876] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[0877] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0878] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0879] bsAb 19
[0880] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 19. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0881] First antigen-binding domain (IL-18)
[0882] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0883] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0884] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0885] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0886] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0887] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0888] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0889] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0890] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0891] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0892] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domaincomprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0893] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0894] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.
[0895] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0896] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0897] Second antigen-binding domain (TL1A)
[0898] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0899] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 226, or a variant or fragment thereof.
[0900] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 227, or a variant or fragment thereof.
[0901] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 226 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 227.In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 228, or a variant or fragment thereof.
[0902] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0903] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 224, or a variant or fragment thereof.
[0904] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0905] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0906] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 225, or a variant or fragment thereof.
[0907] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0908] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 226, a CDR-H3 domain comprising or consisting of SEQ ID No: 227, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 228, and a light chain variable region comprising or consisting of SEQ ID No: 225.
[0909] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[0910] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0911] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0912] bsAb 20
[0913] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 20. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0914] First antigen-binding domain (IL-18)
[0915] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0916] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0917] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0918] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0919] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0920] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0921] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0922] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0923] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0924] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0925] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domaincomprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0926] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0927] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.
[0928] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0929] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0930] Second antigen-binding domain (TL1A)
[0931] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0932] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 220, or a variant or fragment thereof.
[0933] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 237, or a variant or fragment thereof.
[0934] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 237.In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 238, or a variant or fragment thereof.
[0935] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0936] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 224, or a variant or fragment thereof.
[0937] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0938] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0939] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 225, or a variant or fragment thereof.
[0940] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0941] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220, a CDR-H3 domain comprising or consisting of SEQ ID No: 237, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 238, and a light chain variable region comprising or consisting of SEQ ID No: 225.
[0942] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[0943] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0944] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0945] bsAb 21
[0946] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 21. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0947] First antigen-binding domain (IL-18)
[0948] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0949] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0950] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0951] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0952] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0953] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0954] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0955] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0956] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0957] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0958] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domaincomprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0959] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0960] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.
[0961] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0962] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0963] Second antigen-binding domain (TL1A)
[0964] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 230, or a variant or fragment thereof.
[0965] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 220, or a variant or fragment thereof.
[0966] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 222, or a variant or fragment thereof.
[0967] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 230, a CDR-H2 domain comprising or consisting of SEQ ID No: 220 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 222.In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 241, or a variant or fragment thereof.
[0968] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0969] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 224, or a variant or fragment thereof.
[0970] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0971] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0972] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 225, or a variant or fragment thereof.
[0973] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0974] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 230, a CDR-H2 domain comprising or consisting of SEQ ID No: 220, a CDR-H3 domain comprising or consisting of SEQ ID No: 222, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 241, and a light chain variable region comprising or consisting of SEQ ID No: 225.
[0975] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[0976] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0977] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0978] bsAb 22
[0979] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 22. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[0980] First antigen-binding domain (IL-18)
[0981] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[0982] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0983] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0984] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[0985] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0986] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0987] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0988] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0989] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0990] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0991] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domaincomprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0992] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0993] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.
[0994] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[0995] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[0996] Second antigen-binding domain (TL1A)
[0997] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0998] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 220, or a variant or fragment thereof.
[0999] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 239, or a variant or fragment thereof.
[1000] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 239.In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 240, or a variant or fragment thereof.
[1001] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[1002] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 224, or a variant or fragment thereof.
[1003] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[1004] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[1005] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 225, or a variant or fragment thereof.
[1006] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[1007] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220, a CDR-H3 domain comprising or consisting of SEQ ID No: 239, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 240, and a light chain variable region comprising or consisting of SEQ ID No: 225.
[1008] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[1009] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[1010] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[1011] bsAb 23
[1012] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 23. It will be appreciated that this antibody is an anti-IL-18xTLlA CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.
[1013] First antigen-binding domain (IL-18)
[1014] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.
[1015] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[1016] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[1017] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.
[1018] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[1019] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[1020] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[1021] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[1022] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[1023] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[1024] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domaincomprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[1025] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[1026] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.
[1027] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.
[1028] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 123 and a light chain constant region comprising or consisting of SEQ ID No: 124.
[1029] Second antigen-binding domain (TL1A)
[1030] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 230, or a variant or fragment thereof.
[1031] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[1032] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 222, or a variant or fragment thereof.
[1033] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 230, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 222.In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 248, or a variant or fragment thereof.
[1034] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[1035] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 224, or a variant or fragment thereof.
[1036] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[1037] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[1038] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 225, or a variant or fragment thereof.
[1039] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[1040] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 230, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 222, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 248, and a light chain variable region comprising or consisting of SEQ ID No: 225.
[1041] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 125, or a variant or fragment thereof.
[1042] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[1043] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 125 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[1044] In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains consisting of heavy chain variable regions comprising CDR1, CDR2, and CDR3 sequences and light chain variable regions comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 114, 49, or 230, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 220, 50, 226 or 115, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 116, 51, 222, 227, 237 or 239, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 119 or 44, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 120, 45 or 224, or variant sequences thereof comprising 1 , 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions of CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 121 or 46, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof.In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 221, 52, 223, 228, 238, 241, 240 and 248; the light chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 122, 47 and 225.
[1045] Alternatively the bispecific antibody or antigen-binding fragment thereof comprises first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 221, 52, 223, 228, 238, 241, 240 and 248; the light chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 122, 47 and 225. In this context, the term "change" refers to insertions, deletions and / or substitutions.
[1046] The antibody of the invention may comprise or consist of any sequence as defined in Figure 17.
[1047] In one embodiment, the bispecific antibody or antigen-binding fragment according to the first aspect, may comprise a mutated Fc fragment. For example, the bispecific antibody or antigen-binding fragment may be mutated by introducing amino acid substitutions into the Fc region, which silence or reduce the effector function of the antibody, and / or enhance Fc function. Accordingly, in one embodiment, the Fc fragment comprises one or more amino acid substitution that silences or reduces the effector function of the bispecific antibody or antigen-binding fragment thereof.
[1048] In one embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234A, L235A, and P329G, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions L234A, L235A, and P329G. In one embodiment, the ...
Claims
Claims1. A bispecific antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that specifically binds to Interleukin-18 (IL-18) or a functional fragment or variant thereof, and a second antigen-binding domain that specifically binds to Tumour Necrosis Factor-like cytokine 1A (TL1A) or a functional fragment or variant thereof.
2. The bispecific antibody or antigen-binding fragment thereof according to claim 1, wherein the bispecific antibody or antigen-binding fragment thereof binds to one or more amino acids within a sequence comprising or consisting of a sequence as substantially set out in SEQ ID No: 42 and / or SEQ ID No: 43, or a functional fragment or variant thereof.
3. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2:(a) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(b) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 120, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 116;(c) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(d) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) wherein the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 141, a CDR-L2 domain comprising or consisting of SEQ ID No: 142, and a CDR-L3 domain comprising or consisting of SEQ ID No: 143;(e) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 141, a CDR-L2 domain comprising or consisting of SEQ ID No: 142, and a CDR-L3 domain comprising or consisting of SEQ ID No: 143;(f) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising orconsisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 141, a CDR-H2 domain comprising or consisting of SEQ ID No: 142, a CDR-H3 domain comprising or consisting of SEQ ID No: 143, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 116;(g) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(h) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220, a CDR-H3 domain comprising or consisting of SEQ ID No: 222, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(i) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 226, a CDR-H3 domain comprising or consisting of SEQ ID No: 227, a CDR-L1 domain comprising or consisting of SEQ IDNo: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(j) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220, a CDR-H3 domain comprising or consisting of SEQ ID No: 237, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(k) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 230, a CDR-H2 domain comprising or consisting of SEQ ID No: 220, a CDR-H3 domain comprising or consisting of SEQ ID No: 222, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(l) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 220, a CDR-H3 domain comprising or consisting of SEQ ID No: 239, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(m) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, aCDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 230, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 222, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 224, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(n) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 249, a CDR-H2 domain comprising or consisting of SEQ ID No: 250, a CDR-H3 domain comprising or consisting of SEQ ID No: 251, a CDR-L1 domain comprising or consisting of SEQ ID No: 141, a CDR-L2 domain comprising or consisting of SEQ ID No: 142, and a CDR-L3 domain comprising or consisting of SEQ ID No: 143;(o) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 249, a CDR-H2 domain comprising or consisting of SEQ ID No: 250, a CDR-H3 domain comprising or consisting of SEQ ID No: 251, a CDR-L1 domain comprising or consisting of SEQ ID No: 141, a CDR-L2 domain comprising or consisting of SEQ ID No: 142, and a CDR-L3 domain comprising or consisting of SEQ ID No: 143; or(p) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51; and (ii) wherein the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 141, a CDR-H2 domain comprising or consisting of SEQ ID No: 142, a CDR-H3 domain comprising orconsisting of SEQ ID No: 143, a CDR-L1 domain comprising or consisting of SEQ ID No: 249, a CDR-L2 domain comprising or consisting of SEQ ID No: 250, and a CDR-L3 domain comprising or consisting of SEQ ID No: 251.
4. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
5. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 or 37, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 24, 27, 29 or 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26 or 31.
6. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 10 or 13, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, and a CDR-L3 domaincomprising or consisting of SEQ ID No: 3 or 8; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
7. The bispecific antibody or antigen-binding fragment thereof according to claim 3:(a) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122;(b) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 122, and a light chain variable region comprising or consisting of SEQ ID No: 117;(c) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122;(d) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 140, and a light chain variable region comprising or consisting of SEQ ID No: 144;(e) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 140, and a light chain variable region comprising or consisting of SEQ ID No: 144;(f) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52; and (ii) the second antigen-bindingdomain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 144, and a light chain variable region comprising or consisting of SEQ ID No: 140;(g) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 221, and a light chain variable region comprising or consisting of SEQ ID No: 122;(h) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 223, and a light chain variable region comprising or consisting of SEQ ID No: 225;(i) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 228, and a light chain variable region comprising or consisting of SEQ ID No: 225;(j) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 238, and a light chain variable region comprising or consisting of SEQ ID No: 225;(k) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 241, and a light chain variable region comprising or consisting of SEQ ID No: 225;(l) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 240, and a light chain variable region comprising or consisting of SEQ ID No: 225; or(m) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 248, and a light chain variable region comprising or consisting of SEQ ID No: 225.
8. The bispecific antibody or antigen-binding fragment thereof according to claim 4, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
9. The bispecific antibody or antigen-binding fragment thereof according to claim 5, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 39, and a light chain variable region comprising or consisting of SEQ ID No: 38.
10. The bispecific antibody or antigen-binding fragment thereof according to claim 6, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 15, and a light chain variable region comprising or consisting of SEQ ID No: 14; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
11. The bispecific antibody or antigen-binding fragment thereof according to claim 4, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 40, and a light chain variable region comprising or consisting of SEQ ID No: 39.
12. The bispecific antibody or antigen-binding fragment thereof according to claim 4, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 16, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
13. The bispecific antibody or antigen-binding fragment thereof according to any preceding claim, wherein the bispecific antibody or antigen-binding fragment thereof comprises a mutated Fc fragment, optionally wherein:(i) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234A, L235A, and P329G, according to EU numbering;(ii) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: N325S and L328F, according to EU numbering;(iii) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: M252Y, S254T, and T256E, according to EU numbering;(iv) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234F, L235E and P331S, according to EU numbering;(v) the Fc fragment of the first or second antigen-binding domain comprises a T366W amino acid substitution, and the Fc fragment of the first or second antigenbinding domain comprises the amino acid substitutions T366S, L368A, and Y407V, according to EU numbering; and / or(vi) the Fc fragment of the first or second antigen-binding domain comprises a F405L amino acid substitution, and the Fc fragment of the first or second antigenbinding domain comprises a K409R amino acid substitution, according to EU numbering.
14. An antibody or antigen-binding fragment thereof that specifically binds to IL-18, and comprises:(i) a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, 80, 84, 101, or 104, or a variant or fragment thereof;(ii) a CDR-H2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 45, 58, 62, 64, 68, 70, 72, 78, 82, 86, 88, 90, or 102, or a variant or fragment thereof;(iii) a CDR-H3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 46, 60, or 106, or a variant or fragment thereof;(iv) a CDR-L1 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 49, 54, 56, or 74, or a variant or fragment thereof;(v) a CDR-L2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 50, 66, or 93, or a variant or fragment thereof; and / or(vi) a CDR-L3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 51, 76, 94, or 108, or a variant or fragment thereof.
15. The antibody or antigen-binding fragment thereof according to claim 14, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of any one of SEQ ID Nos: 47, 59, 61, 63, 65, 69, 71, 73, 79, 81, 83, 85, 87, 89, 91, 92, 97, 99, 103, 105, 107, 110, 112, or 113, and a light chain variable region comprising or consisting of any one of SEQ ID Nos: 52, 55, 57, 67, 75, 77, 95, 96, 100, 109, or 111.
16. An antibody or antigen-binding fragment thereof that specifically binds to TL1A, and comprises:(i) a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114 or 230, or a variant or fragment thereof; (ii) a CDR-H2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 220, 226 or 115, or a variant or fragment thereof;(iii) a CDR-H3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 116, 222, 227, 231, 233, 237, 239, 242, 116 or 246, or a variant or fragment thereof;(iv) a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof;(v) a CDR-L2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 120, 224 or 235, or a variant or fragment thereof; and / or(vi) a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
17. The antibody or antigen-binding fragment thereof according to claim 18, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of any one of SEQ ID Nos: 221, 223, 228, 229, 232, 234, 238, 240, 241, 243, 244, 245, 247 or 248, and a light chain variable region comprising or consisting of any one of SEQ ID Nos: 122, 225 or 236.
18. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, for use in therapy.
19. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, for use in treating, preventing or ameliorating a condition mediated by IL-18 and / or TL1A.
20. The bispecific antibody or antigen-binding fragment thereof, or the antibody or antigen-binding fragment thereof, for use according to claim 19, wherein the condition mediated by IL-18 and / or TL1A is selected from the group consisting of: Atopic Dermatitis (AD), Systemic Juvenile Idiopathic Arthritis (sJIA), Adult-Onset Still's Disease (AOSD), Macrophage Activation Syndrome (MAS), Hemophagocytic Lymphohistiocytosis (HLH), Inflammatory Bowel Disease (IBD) including Crohn's Disease, Ulcerative Colitis, and Fibrostenotic Crohn's Disease, Multiple Sclerosis (MS) and Neuroinflammation, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease (COPD), Asthma, Pulmonary Fibrosis, Interstitial Lung Disease (ILD), Infections, Sepsis and Cytokine Storm Syndromes, Primary Sclerosing Cholangitis (PSC), Scleroderma, Alopecia Areata, Rheumatoid Arthritis, Psoriatic Arthritis, Autoimmune Hepatitis, Systemic Lupus Erythematosus (SLE), Psoriasis, and Type 1 Diabetes (T1D).
21. A pharmaceutical composition comprising the bispecific antibody or antigenbinding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, and optionally a pharmaceutically acceptable vehicle.
22. A process for making the pharmaceutical composition according to claim 21, the process comprising combining a therapeutically effective amount of the bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, with a pharmaceutically acceptable vehicle.
23. One or more polynucleotide sequence encoding the bispecific antibody or antigen binding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17.
24. An expression cassette comprising one or more polynucleotide sequence according to claim 23.
25. A recombinant vector comprising the expression cassette according to claim 24.
26. A host cell comprising the one or more polynucleotide sequence according to claim 23, the expression cassette according to claim 24, or the vector according to claim 25.
27. A method of preparing the bispecific antibody or antigen binding fragment according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, the method comprising:a) introducing, into a host cell, the vector of claim 25; andb) culturing the host cell under conditions to result in the production of the bispecific antibody or antigen binding fragment according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17.
28. The bispecific antibody or antigen-binding fragment according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, for use in diagnosis or prognosis.
29. The bispecific antibody or antigen-binding fragment according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, for use in diagnosing or prognosing a condition mediated by IL-18 and / or TL1A.
30. A method of diagnosing or prognosing a condition mediated by IL-18 and / or TL1A in a subject, the method comprising detecting IL-18 and / or TL1A in a biological sample obtained from the subject with the bispecific antibody or antigen-binding fragment according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17.
31. A kit for diagnosing a subject suffering from a condition mediated by IL-18 and / or TL1A, or for providing a prognosis of the subject's condition, the kit comprising the bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, for detecting IL-18 and / or TL1A in a sample from a test subject.
